Loading...
•
Jun 30, 2021
SIGA Technologies Q2 2021 Earnings Report
SIGA Technologies' financial results for Q2 2021 reflected a decrease in total revenues and net income compared to Q2 2020, but international revenues from oral TPOXX® showed a steady positive result.
Key Takeaways
SIGA Technologies reported Q2 2021 financial results with a decrease in total revenues to $8.7 million compared to $40.3 million in Q2 2020. Net income decreased to $0.2 million from $20.9 million in the same period last year. However, the company saw $7 million in international revenues from oral TPOXX® deliveries to Canada.
Total revenues for the second quarter of 2021 were $8.7 million, compared to $40.3 million for the second quarter of 2020.
Net income for the second quarter of 2021 was $0.2 million, compared to $20.9 million for the second quarter of 2020.
The company delivered approximately $7 million of oral TPOXX® to PHAC under the contract awarded in January 2021.
SIGA filed a new drug application with the FDA for the intravenous formulation of TPOXX.
Revenue by Segment
Forward Guidance
The company is working with Meridian in a new foreign jurisdiction toward finalizing an order that would be similar in size to the initial orders received from Canada in 2020 and early 2021. The timing of the completion of the order has been, and may continue to be impacted by the COVID-19 pandemic.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...